Atypical femoral fracture, case report and literature review

Bisphosphonates have been the gold standard in the management of osteoporosis. Its antiresorptive effect has reduced the incidence of fractures due to bone fragility, as well as its impact on public health. We present the clinical case of a patient in prolonged treatment with bisphosphonates and atypical bilateral femur fracture.

A 65-year-old female who presented a fall from her own height, on treatment with risedronate for seven years, and a history of systemic arterial hypertension and hypercholesterolemia, both with medical treatment. Diagnosed with bilateral atypical femoral fracture, treated with closed reduction internal fixation (CRIF) with intramedullary nailing, application of calcium citrate and teriparatide.

Multiple studies indicate that the benefit of using bisphosphonates for osteoporosis is higher than the risk of presenting atypical fractures.